03.29.24
A new study from researchers at Boston University Chobanian & Avedisian School of Medicine has validated a novel scale for hyperpigmentation the Post-inflammatory Dyspigmentation Area and Severity Index (PIDASI) in a diverse US population of varying skin tones. The researchers also developed and validated a new scale for the condition. The new Post Inflammatory Hyperpigmentation Area and Severity Index (PIHASI) allows for better and easier characterization of the condition, according to the researchers.
“Our study demonstrates that both the PIDASI and PIHASI tools perform well in patients of a variety of skin types with post-inflammatory hyperpigmentation and are reliable and valid alternatives to the commonly used metric to measure the severity of skin changes from inflammatory diseases,” noted corresponding author Neelam Vashi, MD, associate professor of dermatology at the school and director of the Boston University Cosmetic and Laser Center at Boston Medical Center.
Patients with hyperpigmentation were examined using colorimetry, an objective method of color characterization and standardized photographs. Expert dermatologists and dermatology residents then graded the hyperpigmentation on three scales; the scale they created (PIHASI), the PIDASI, and the industry standard. They found that both PIDASI and PIHASI corresponded to objective measurements of disease severity.
According to the researchers, the PIHASI scale will allow providers to better characterize a patient's hyperpigmentation and will be vital in hyperpigmentation research to better quantify response to treatment. “As the scale is simpler than the PIDASI, it can also be used in clinics during patient encounters to understand improvement in hyperpigmentation across time,” said Vashi.
The findings appeared online in the Journal of the American Academy of Dermatology.
Hyperpigmentation Treatments with Dr. Andrew Alexis, MD
“Our study demonstrates that both the PIDASI and PIHASI tools perform well in patients of a variety of skin types with post-inflammatory hyperpigmentation and are reliable and valid alternatives to the commonly used metric to measure the severity of skin changes from inflammatory diseases,” noted corresponding author Neelam Vashi, MD, associate professor of dermatology at the school and director of the Boston University Cosmetic and Laser Center at Boston Medical Center.
Patients with hyperpigmentation were examined using colorimetry, an objective method of color characterization and standardized photographs. Expert dermatologists and dermatology residents then graded the hyperpigmentation on three scales; the scale they created (PIHASI), the PIDASI, and the industry standard. They found that both PIDASI and PIHASI corresponded to objective measurements of disease severity.
According to the researchers, the PIHASI scale will allow providers to better characterize a patient's hyperpigmentation and will be vital in hyperpigmentation research to better quantify response to treatment. “As the scale is simpler than the PIDASI, it can also be used in clinics during patient encounters to understand improvement in hyperpigmentation across time,” said Vashi.
The findings appeared online in the Journal of the American Academy of Dermatology.
Related Content
L’Oréal’s Proprietary Melasyl Ingredient Debuts in LaRoche-Posay FormulationsHyperpigmentation Treatments with Dr. Andrew Alexis, MD